Chief Operating Officer
Prior to joining Apnimed, he led U.S. operations of Helperby Therapeutics LTD as Chief Executive from 2016 to 2018. Helperby Therapeutics develops novel combination antibiotics to treat multi-drug resistant bacterial infections. From 2014-2016 he consulted for a number of anti-infective companies, helping them with their development, regulatory and financing strategies. From 2001 to 2014, he held a series of positions of increasing responsibility at Paratek Pharmaceuticals, Inc. located in Boston, MA. Paratek Pharmaceuticals develops novel tetracycline antibiotics. From 2012-2014 he was CEO of Paratek Pharmaceuticals, helping to take the company public through a reverse merger with Transcept Pharmaceuticals in 2014. Prior to Paratek, he was the President of JBI Associates, a consultancy for hospital pharmacies from 2000-2001. From 1998-2000 he served as the Director of Finance and Business Development at Magainin Pharmaceuticals in Plymouth Meeting, PA. He worked as a consultant at Bogart Delafield Ferrier, a strategic healthcare consulting firm located in Morristown, NJ from 1993-1996. From 1991-1993 he worked as a financial consultant at Merrill Lynch located in Somerville, NJ. He holds a BA in Economics and Biology from Brown University and MBA in Health Care Management from the University of Pennsylvania, Wharton School.